On Thursday, Shares of Publicis Groupe SA (EPA:PUB), gained 15.17% to $ 16.70.
Publicis Groupe, declared the pricing of its initial public offering of 2,500,000 common shares at a public offering price of $14.50 per share. The shares will be listed on the NASDAQ Capital Market and will trade under the ticker symbol “PUB” starting on June 11, 2015. The Company is offering 2,282,000 common shares and certain shareholders are offering 218,000 common shares. The underwriters have an option, exercisable until July 10, 2015, to purchase up to an additional 375,000 common shares from the Company at the public offering price less the underwriting discount. The offering is predictable to close on June 16, 2015.
The Company intends to use the net proceeds from the offering for expansion, both organic and through acquisition, and for general corporate purposes.
People’s Utah Bancorp operates as the bank holding company for Bank of American Fork and Lewiston State Bank that provide commercial banking products and services in the United States. The company offer a range of deposit services, counting checking accounts, savings accounts, and time deposits.
Shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN), inclined 2.58% to $ 2.39, during its last trading session.
Amarin Corporation, declared the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of cholesterol crystalline domains in model biological membranes subjected to high cholesterol levels (to simulate atherosclerotic-like conditions) indicated a level of reduction with EPA that was not reproduced with other triglyceride-lowering agents tested. The poster, titled “Eicosapentaenoic Acid (EPA), But Not Other TG-Lowering Agents, Reduces Cholesterol Domain Levels in Atherosclerotic-Like Model Membranes,” will be presented at the author Q&A session planned for June 13, 2015 from 11:20 a.m.-12:20 p.m. CDT.
“This study was conducted in vitro using model biological membranes under conditions of hypercholesterolemia,” commented Preston Mason, Ph.D., of Brigham and Women’s Hospital and the study’s lead investigator. “The purpose of the study was to examine whether EPA, under atherosclerotic-like conditions, can reduce the formation of cholesterol crystalline domains. Our research team found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65% (p<0.05) as contrast to vehicle-treated (ethanol) controls.”
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product comprises Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
At the end of Thursday’s trade, Shares of Xilinx, Inc. (NASDAQ:XLNX), gained 0.47% to $ 47.22.
Xilinx, declared that it was presented the winner of the Outstanding Components Vendor category in the 2015 Leading Lights Awards, organized by Light Reading publication. Xilinx was chosen from a field that comprised of six other entrants at the Leading Lights awards dinner in Chicago on Monday, June 8, coinciding with the Big Telecom Event. The Outstanding Components Vendor category recognized the vendor that stands out from its competitors, innovates constantly, assists set the industry trends, makes investors proud, and makes employees happy.
“The quality of the entries across all the categories was extremely high, resulting in a very compelling group of finalists,” said Light Reading Editor-in-Chief Ray Le Maistre. “They also reflect the ongoing innovation we’re all witnessing in the communications services and technology sectors.”
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards; and intellectual property (IP), which comprises of Xilinx and various third-party verification and IP cores.
Finally, Agilent Technologies Inc (NYSE:A), ended its last trade with 0.02% gain, and close at $ 40.53.
Agilent Technologies, declared a formal agreement to exchange instrument controls to improve the productivity of customers who own software and instruments from both companies.
The new agreement replaces earlier provisions under which Agilent implemented control of Waters instruments in the Agilent OpenLAB chromatography data system and Waters implemented control of Agilent liquid chromatography instruments in Waters Empower Software.
Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
